Cormio Gennaro, Di Fazio Franco, Cacciapuoti Cinzia, Bettocchi Stefano, Borraccino Luisella, Selvaggi Luigi
Sezione di Ginecologia A, Dipartimento di Scienze Chirurgiche Generali e Specialistiche, Università degli Studi di Bari, Italy.
Acta Obstet Gynecol Scand. 2003 Dec;82(12):1130-4. doi: 10.1046/j.1600-0412.2003.00236.x.
To compare amoxicillin-clavulanic acid with cefazolin as ultra-short-term prophylaxis in laparotomic gynecologic surgery.
A prospective randomized study was conducted to compare two antimicrobial regimens in surgical prophylaxis of laparotomic surgery. Patients were randomly allocated to receive amoxicillin-clavulanic acid (2.2 g) [Group A] or cefazolin (2 g) [Group B] as a single dose 30 min before surgery. Each patient was assessed daily until discharge to evidence febrile status and the presence of infections at the operative site, urinary tract, and respiratory tract.
In the amoxicillin-clavulanic acid (Group A) and cefazolin (Group B) groups, overall 346 and 352 patients, respectively, were evaluable for prophylactic efficacy at hospital discharge. Infectious complications were infrequent in both arms. Febrile morbidity occurred in 21 (6.1%) and 26 (7.4%) patients, respectively, in the amoxicillin-clavulanic acid and cefazolin groups. Wound infection and urinary tract infection were also higher, but not significantly in the cefazolin group (0.5% vs. 1.1% and 2.0% vs. 2.5%, respectively). There was one respiratory tract infection (0.2%) in Group B, and no septic death in either groups.
Ultra-short-term prophylaxis with both amoxicillin-clavulanic acid and cefazolin is safe in elective laparotomic gynecologic surgery.
比较阿莫西林-克拉维酸与头孢唑林在开腹妇科手术中作为超短期预防用药的效果。
进行一项前瞻性随机研究,比较两种抗菌方案在开腹手术预防性应用中的效果。患者被随机分配,在手术前30分钟接受单剂量的阿莫西林-克拉维酸(2.2克)[A组]或头孢唑林(2克)[B组]。对每位患者每日进行评估,直至出院,以证明发热状态以及手术部位、泌尿道和呼吸道是否存在感染。
在阿莫西林-克拉维酸组(A组)和头孢唑林组(B组),分别有346例和352例患者在出院时可评估预防效果。两组感染并发症均不常见。阿莫西林-克拉维酸组和头孢唑林组分别有21例(6.1%)和26例(7.4%)患者出现发热性疾病。头孢唑林组的伤口感染和泌尿道感染也较高,但差异无统计学意义(分别为0.5%对1.1%和2.0%对2.5%)。B组有1例呼吸道感染(0.2%),两组均无败血症死亡病例。
在择期开腹妇科手术中,阿莫西林-克拉维酸和头孢唑林的超短期预防用药均安全。